158 related articles for article (PubMed ID: 31876082)
1. Clinical manifestations of Pacak-Zhuang syndrome in a male pediatric patient.
Abdallah A; Pappo A; Reiss U; Shulkin BL; Zhuang Z; Pacak K; Bahrami A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28096. PubMed ID: 31876082
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia and paraganglioma with a novel somatic HIF2A mutation in a male.
Toyoda H; Hirayama J; Sugimoto Y; Uchida K; Ohishi K; Hirayama M; Komada Y
Pediatrics; 2014 Jun; 133(6):e1787-91. PubMed ID: 24819565
[TBL] [Abstract][Full Text] [Related]
3. A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2α as the major player in its pathogenesis and future therapeutic options.
Jochmanova I; Lazurova I
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):175-80. PubMed ID: 24781045
[TBL] [Abstract][Full Text] [Related]
4. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
[TBL] [Abstract][Full Text] [Related]
5. Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
Kamihara J; Hamilton KV; Pollard JA; Clinton CM; Madden JA; Lin J; Imamovic A; Wall CB; Wassner AJ; Weil BR; Heeney MM; Vargas SO; Kaelin WG; Janeway KA; Perini RF; Zojwalla NJ; Voss SD; DuBois SG
N Engl J Med; 2021 Nov; 385(22):2059-2065. PubMed ID: 34818480
[TBL] [Abstract][Full Text] [Related]
6. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.
Buffet A; Smati S; Mansuy L; Ménara M; Lebras M; Heymann MF; Simian C; Favier J; Murat A; Cariou B; Gimenez-Roqueplo AP
J Clin Endocrinol Metab; 2014 Feb; 99(2):E369-73. PubMed ID: 24276449
[TBL] [Abstract][Full Text] [Related]
7. Pacak-Zhuang syndrome: a model providing new insights into tumor syndromes.
Rosenblum JS; Wang H; Nazari MA; Zhuang Z; Pacak K
Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37450881
[TBL] [Abstract][Full Text] [Related]
8. HIF2A mutations in paraganglioma with polycythemia.
Favier J; Buffet A; Gimenez-Roqueplo AP
N Engl J Med; 2012 Nov; 367(22):2161; author reply 2161-2. PubMed ID: 23190243
[No Abstract] [Full Text] [Related]
9. Chiari Malformation Type 1 in
Rosenblum JS; Maggio D; Pang Y; Nazari MA; Gonzales MK; Lechan RM; Smirniotopoulos JG; Zhuang Z; Pacak K; Heiss JD
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185588
[TBL] [Abstract][Full Text] [Related]
10.
Nagano Y; Inoue M; Uchida K; Otake K; Kusunoki M
Pediatr Int; 2020 Feb; 62(2):231-232. PubMed ID: 32104990
[No Abstract] [Full Text] [Related]
11. Ocular manifestations of hypoxia-inducible factor-2α paraganglioma-somatostatinoma-polycythemia syndrome.
Pacak K; Chew EY; Pappo AS; Yang C; Lorenzo FR; Wilson MW; Aronow MB; Young JA; Popovic V; Zhuang Z
Ophthalmology; 2014 Nov; 121(11):2291-3. PubMed ID: 25109928
[No Abstract] [Full Text] [Related]
12. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.
Zhuang Z; Yang C; Lorenzo F; Merino M; Fojo T; Kebebew E; Popovic V; Stratakis CA; Prchal JT; Pacak K
N Engl J Med; 2012 Sep; 367(10):922-30. PubMed ID: 22931260
[TBL] [Abstract][Full Text] [Related]
13. Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome.
Dmitriev PM; Wang H; Rosenblum JS; Prodanov T; Cui J; Pappo AS; Gilbert MR; Lutty GA; Chan CC; Chew EY; Pacak K; Zhuang Z
JAMA Ophthalmol; 2020 Feb; 138(2):148-155. PubMed ID: 31876943
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
[TBL] [Abstract][Full Text] [Related]
15. Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome.
Pang Y; Gupta G; Jha A; Yue X; Wang H; Huynh TT; Li A; Li L; Baker E; Chew E; Feelders RA; Korpershoek E; Zhuang Z; Yang C; Pacak K
Cancer; 2019 Apr; 125(8):1258-1266. PubMed ID: 30644531
[TBL] [Abstract][Full Text] [Related]
16. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
[TBL] [Abstract][Full Text] [Related]
17. Duodenal somatostatinoma and erythrocytosis in a patient with von Hippel-Lindau disease type 2A.
Karasawa Y; Sakaguchi M; Minami S; Kitano K; Kawa S; Aoki Y; Itoh N; Sakurai A; Miyazaki M; Watanabe T; Akimoto M; Arakura N; Kiyosawa K
Intern Med; 2001 Jan; 40(1):38-43. PubMed ID: 11201368
[TBL] [Abstract][Full Text] [Related]
18. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.
Taïeb D; Yang C; Delenne B; Zhuang Z; Barlier A; Sebag F; Pacak K
J Clin Endocrinol Metab; 2013 May; 98(5):E908-13. PubMed ID: 23539726
[TBL] [Abstract][Full Text] [Related]
19. HIF2 and endocrine neoplasia: an evolving story.
Maher ER
Endocr Relat Cancer; 2013 Jun; 20(3):C5-7. PubMed ID: 23653463
[TBL] [Abstract][Full Text] [Related]
20. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas.
Yang C; Sun MG; Matro J; Huynh TT; Rahimpour S; Prchal JT; Lechan R; Lonser R; Pacak K; Zhuang Z
Blood; 2013 Mar; 121(13):2563-6. PubMed ID: 23361906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
